We are Protein Degraders. At Proteovant, our team possesses the scientific knowledge, proprietary technologies, business acumen and risk tolerance required to unlock this pioneering field of science and ultimately deliver disease-modifying therapies for patients. We harness the human body’s natural protein degradation machinery to discover and develop transformative new medicines to treat patients with life-altering diseases. With our approach, we are able to pursue previously undruggable disease targets and pioneer this expansive field with speed and scale. We integrate extensive medicinal chemistry and biology intuition with deep, proprietary artificial intelligence capabilities – resulting in a robust pipeline that spans a range of therapeutic areas and novel molecular targets. We are funded by Roivant Sciences and SK Holdings. For more information, please visit our website at www.proteovant.com